Navigation Links
Renhuang Announces Price Increase on Shengmai Granules
Date:3/11/2010

HARBIN, China, March 11 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today that it has recently increased its Shengmai Granules price by 12%. Shengmai Granule is an all-natural traditional Chinese medicine that alleviates female gynecological complications.

The price increase followed guidelines set by the National Development and Reform Commission (NDRC), a Chinese government economic panel, in October 2009. The Company increased the price on Shengmai Granules based on continued strong sales volume and market demand for the product.

"While we had assumed a price increase for Shengmai Granules in our outlook, the ability to quickly implement this price increase reinforces our confidence in the fiscal 2010 guidance," said Mr. Shaoming Li, Renhuang's Chairman and CEO. "Renhuang remains committed to delivering the best value proposition for our customers by providing high quality healthcare products and investing in the development of new products to meet patient needs."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit the company's website (http://www.renhuang.com ).

Safe Harbor Statement This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to continue to increase prices, to meet financial guidance, to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:

     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone:   +86-451-5392-5461
     Email:   ir@renhuang.com
     Website: http://www.renhuang.com

    CCG Investor Relations:

     Ms. Lei Huang, Account Manager
     Phone:   +1-646-833-3417 (New York)
     Email:   lei.huang@ccgir.com
     Website: http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone:   +1-646-213-1915 (New York)
     Email:   crocker.coulson@ccgir.com

SOURCE Renhuang Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.renhuang.com

'/>"/>

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:5/2/2016)... May 2, 2016 The ... USD 11.1 billion by 2024, according to a ... Major drivers of the sonography market include expanding ... government recommendations for periodic ultrasound screenings of the ... http://photos.prnewswire.com/prnh/20150105/723757 ) High Intensity ...
Breaking Medicine Technology:
(Date:5/2/2016)... CHICAGO (PRWEB) , ... May 02, 2016 , ... ... comprehensive treatment for eating, mood and anxiety disorders, has rebranded its eating disorder program ... a new residential eating disorder treatment facility on May 16. , To celebrate, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... Vegas, NV (PRWEB) , ... May 02, 2016 ... ... Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that ... determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... prescription medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering drugs, may cause cognitive ... Detox Center —a leading Florida-based drug treatment facility—advises patients to research the ...
Breaking Medicine News(10 mins):